UBS Group Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price

Baxter International (NYSE:BAX) had its price target decreased by investment analysts at UBS Group from $24.00 to $21.00 in a report released on Friday, MarketBeat.com reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group’s target price would indicate a potential upside of 13.73% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. The Goldman Sachs Group downgraded shares of Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 price objective for the company. in a research note on Friday, August 1st. Wells Fargo & Company reduced their price target on Baxter International from $33.00 to $24.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Evercore ISI dropped their price objective on Baxter International from $33.00 to $31.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Citigroup reduced their target price on shares of Baxter International from $34.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, July 9th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $25.00 price target (down from $36.00) on shares of Baxter International in a research report on Monday, August 4th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $23.70.

Baxter International Stock Performance

BAX stock opened at $18.47 on Friday. Baxter International has a 1-year low of $18.42 and a 1-year high of $37.74. The business has a 50-day moving average price of $23.14 and a 200 day moving average price of $26.85. The company has a market capitalization of $9.48 billion, a P/E ratio of -61.55, a PEG ratio of 0.73 and a beta of 0.58. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.30 and a quick ratio of 1.49.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.88 billion. During the same quarter last year, the firm posted $0.80 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. As a group, equities research analysts forecast that Baxter International will post 2.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Baxter International

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank boosted its holdings in Baxter International by 1.9% during the first quarter. Amalgamated Bank now owns 100,118 shares of the medical instruments supplier’s stock worth $3,427,000 after buying an additional 1,897 shares in the last quarter. Rossby Financial LCC purchased a new stake in shares of Baxter International during the 1st quarter worth about $29,000. Private Trust Co. NA grew its position in shares of Baxter International by 17.3% during the 1st quarter. Private Trust Co. NA now owns 3,822 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 565 shares during the period. TD Private Client Wealth LLC raised its holdings in Baxter International by 21.5% in the 1st quarter. TD Private Client Wealth LLC now owns 47,438 shares of the medical instruments supplier’s stock worth $1,624,000 after purchasing an additional 8,393 shares during the period. Finally, ARGA Investment Management LP boosted its position in Baxter International by 52.5% during the first quarter. ARGA Investment Management LP now owns 1,327,946 shares of the medical instruments supplier’s stock worth $45,456,000 after purchasing an additional 457,345 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.